<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13(1)</volume><submitter>Wu N</submitter><pubmed_abstract>The clinical significance of necroptosis in gastric cancer (GC) has yet to be fully elucidated. The purpose of our study was to identify a necroptosis-relevant gene and to establish a prediction model to estimate the prognosis and therapeutic potential in GC. Here, we explored the expression profile of 76 necroptosis-related genes in TCGA-STAD patients. A six-gene risk score prediction model was established via regression analysis of the least absolute shrinkage and selection operator (LASSO) and validated in a separate cohort. Patients were separated into low- or high-risk groups according to the median risk score. We then compared and analyzed the biological process characteristics of two risk groups. Additionally, cell-to-cell communications and metabolic activity were analyzed in a single-cell solution. The in vitro experiments were conducted to explore the biological functions and drug sensitivity of necroptosis-related genes in gastric cancer. Our results identified that compared with the low-risk group, the high-risk group was associated with a higher clinical stage or grade and a worse prognosis. In addition, the low-risk group had higher levels of immunity and immune cell infiltration. Necroptosis was triggered by the TNF pathway in myeloid cells and the glycolysis pathway was altered. Necroptosis-related genes modulated the cell function, including proliferation and migration in vitro. Furthermore, the potential drugs' sensitivity was higher in the low-risk subgroup. These findings could facilitate a better understanding and improve the treatment potential and prognosis of GC patients.</pubmed_abstract><journal>Biomolecules</journal><pagination>101</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9856014</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Necroptosis Related Genes Predict Prognosis and Therapeutic Potential in Gastric Cancer.</pubmed_title><pmcid>PMC9856014</pmcid><pubmed_authors>Yu L</pubmed_authors><pubmed_authors>Huang Y</pubmed_authors><pubmed_authors>Wu N</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Liu B</pubmed_authors><pubmed_authors>Su X</pubmed_authors><pubmed_authors>Liu F</pubmed_authors></additional><is_claimable>false</is_claimable><name>Necroptosis Related Genes Predict Prognosis and Therapeutic Potential in Gastric Cancer.</name><description>The clinical significance of necroptosis in gastric cancer (GC) has yet to be fully elucidated. The purpose of our study was to identify a necroptosis-relevant gene and to establish a prediction model to estimate the prognosis and therapeutic potential in GC. Here, we explored the expression profile of 76 necroptosis-related genes in TCGA-STAD patients. A six-gene risk score prediction model was established via regression analysis of the least absolute shrinkage and selection operator (LASSO) and validated in a separate cohort. Patients were separated into low- or high-risk groups according to the median risk score. We then compared and analyzed the biological process characteristics of two risk groups. Additionally, cell-to-cell communications and metabolic activity were analyzed in a single-cell solution. The in vitro experiments were conducted to explore the biological functions and drug sensitivity of necroptosis-related genes in gastric cancer. Our results identified that compared with the low-risk group, the high-risk group was associated with a higher clinical stage or grade and a worse prognosis. In addition, the low-risk group had higher levels of immunity and immune cell infiltration. Necroptosis was triggered by the TNF pathway in myeloid cells and the glycolysis pathway was altered. Necroptosis-related genes modulated the cell function, including proliferation and migration in vitro. Furthermore, the potential drugs' sensitivity was higher in the low-risk subgroup. These findings could facilitate a better understanding and improve the treatment potential and prognosis of GC patients.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2025-04-22T09:06:55.143Z</modification><creation>2025-04-05T22:50:31.786Z</creation></dates><accession>S-EPMC9856014</accession><cross_references><pubmed>36671486</pubmed><doi>10.3390/biom13010101</doi></cross_references></HashMap>